Trials / Completed
CompletedNCT05133505
Characterisation of TIM-3/Gal-9 Immune Checkpoints in Primary Central Nervous System Diffuse Large B Cell Lymphomas
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 65 (actual)
- Sponsor
- University Hospital, Montpellier · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Primary central nervous system diffuse large B cell lymphoma is a rare and aggressive entity of diffuse large B cell lymphoma. A previous transcriptomic study showed an overexpression of TIM-3 and Gal-9 in the tumor microenvironment. The investigators aimed to characterise TIM-3/Gal-9 immune checkpoints by using immunohistochemistry in the tumor microenvironment of primary central nervous system diffuse large B cell lymphoma.
Conditions
Timeline
- Start date
- 2002-01-01
- Primary completion
- 2021-10-01
- Completion
- 2021-11-01
- First posted
- 2021-11-24
- Last updated
- 2021-11-24
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT05133505. Inclusion in this directory is not an endorsement.